High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma

BJU International

Volumn 102, Issue 11, 2008, Pages 1700-1706

  Haferkamp, Axel ^a   Bedke, Jens ^a   Vetter, Caroline ^a   Pritsch, Maria ^a   Wagener, Nina ^a,b   Buse, Stephan ^a   Crnkovic Mertens, Irena ^b   Hoppe Seyler, Karin ^b   Macher Goeppinger, Stephan ^a,b   Hoppe Seyler, Felix ^b   Autschbach, Frank ^a,b   Hohenfellner, Markus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis inhibitor; Livin; Long term survival; Renal cell carcinoma

Indexed keywords

LIVIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEPHRECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 56649108320     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07910.x     Document Type: Article

References (29)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005 353 : 2477 90
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999 281 : 1628 31
3. Fisher R, Rosenberg S, Fyfe G. Long-term survival update for high-dose interleukin-2 in patients with metastatic renal cell carcinoma. Cancer J Sci Am 2000 6 (Suppl. 1 S55 7
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 24
5. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 34
6. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 370 : 2103 11
7. Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park) 2007 21 : 1175 80
8. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000 27 : 177 86
9. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000 21 : 485 95
10. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002 2 : 277 88
11. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999 17 : 2941 53
12. Aravind L, Dixit VM, Koonin EV. The domains of death: evolution of the apoptosis machinery. Trends Biochem Sci 1999 24 : 47 53
13. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002 3 : 401 10
14. Ramp U, Krieg T, Caliskan E et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 2004 35 : 1022 8
15. Parker AS, Kosari F, Lohse CM et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006 107 : 37 45
16. Wagener N, Crnkovic-Mertens I, Vetter C et al. Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney. Br J Cancer 2007 97 : 1271 6
17. Kitamura H, Honma I, Torigoe T et al. Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients. Urology 2007 70 : 38 42
18. Kempkensteffen C, Hinz S, Christoph F et al. Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol 2007 28 : 132 8
19. Xiang Y, Yao H, Wang S et al. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. The Laryngoscope 2006 116 : 126 30
20. Kim DK, Alvarado CS, Abramowsky CR et al. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol 2005 8 : 621 9
21. Li JH, He WJ, He YJ. [Expression and clinical significance of Survivin and Livin in DukesoB colorectal cancer]. Ai Zheng 2007 26 : 547 51
22. Gazzaniga P, Gradilone A, Giuliani L et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003 14 : 85 90
23. Gordon GJ, Mani M, Mukhopadhyay L et al. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007 211 : 447 54
24. Choi J, Hwang YK, Sung KW et al. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007 109 : 471 7
25. Campos L, Sabido O, Sebban C et al. Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia 1996 10 : 434 8
26. Coustan Smith E, Kitanaka A, Pui CH et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996 87 : 1140 6
27. Nachmias B, Ashhab Y, Bucholtz V et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res 2003 63 : 6340 9
28. Nachmias B, Lazar I, Elmalech M et al. Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin. Apoptosis 2007 12 : 1129 42
29. Nedelcu T, Kubista B, Koller A et al. Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol 2008 134 : 237 44